With lawyers across Canada, the United States, the United Kingdom, the European Union, Australia, the Middle East and Asia Pacific, we provide coordinated legal advice on product development, regulatory strategy, market access, transactions and enforcement—wherever our clients operate in the world. We are consistently recognized by Chambers and Partners and The Legal 500 as a leading law firm for life sciences and healthcare legal matters.
With more than 3,000 lawyers in 50 offices worldwide, we were the first global law firm to develop a dedicated Healthcare legal practice and have been advising healthcare organizations for more than 85 years.
We have a notable history representing drug, device, biologics and healthcare systems innovators in transactions, intellectual property, investigations and some of the most significant litigation matters of the last three decades.
Our Life Sciences and Healthcare lawyers advise across the full product lifecycle, acting for clients developing and commercializing small-molecule drugs, biologics, biosimilars, cell and gene therapies, medical devices, diagnostics, digital health technologies and combination products across multiple jurisdictions.
Contacts
secondary
Common questions answered
What legal services does Norton Rose Fulbright provide to life sciences and healthcare companies?
Our practice is organized across six core areas, covering the legal issues that most directly affect life sciences and healthcare clients across innovation, development, market access and commercial operations:
- Regulatory pathways and compliance, including clinical trials, marketing approvals, post‑authorization obligations and product safety
- Transactions and strategic arrangements, including acquisitions, divestments, licensing, collaborations and joint ventures
- Intellectual property, including protection, enforcement and freedom‑to‑operate strategy
- Pricing, reimbursement and market access, including competition considerations, procurement and government programs
- Investigations and enforcement risk, including healthcare fraud, anti‑bribery and corruption, and regulatory inquiries
- Disputes, including product liability, commercial disputes and proceedings before courts and regulators
Who are Norton Rose Fulbright’s life sciences clients?
Our Life Sciences lawyers advise pharmaceutical, biotechnology, medical device, consumer health (including natural health products and over-the-counter (OTC) medicines) and health technology companies from early-stage research and clinical development through global commercialization. Clients include global brands, regional companies, start-ups and distributors operating across the development and commercialization spectrum.
Our work includes:
- Authorization pathways, labeling, pharmacovigilance and post‑approval obligations
- Manufacturing, distribution and supply arrangements
- Pipeline, portfolio and strategic transactions
- Patent development, enforcement and lifecycle planning
- Pricing, reimbursement and competition considerations
- Commercial and product liability litigation
- Regulatory investigations
As regulatory frameworks continue to evolve—across the US Food and Drug Administration (FDA), European Medicines Agency (EMA), UK Medicines and Healthcare products Regulatory Agency (MHRA), Health Canada and equivalent agencies worldwide—Norton Rose Fulbright lawyers provide the continuity of advice and sector knowledge that life sciences clients need at every stage of the product and business lifecycle.
Which healthcare organizations does Norton Rose Fulbright advise?
Our Healthcare law team advises hospitals, health systems, academic medical centers, physician groups, payors, insurers, private equity investors, universities, clinics, long-term care providers, pharmacies, distributors, public bodies and digital health companies. We advise on the legal, regulatory and operational frameworks governing healthcare services across public and private systems in multiple jurisdictions.
Our healthcare work includes:
- Healthcare regulatory compliance, including HIPAA, the Anti-Kickback Statute, Stark Law, the False Claims Act and equivalent regimes internationally
- Healthcare transactions, including mergers and acquisitions (M&A), financings and affiliations
- Reimbursement and payor disputes
- Telehealth and digital health regulation, including artificial intelligence (AI)
- Healthcare data privacy
- Medical negligence and liability exposure
- Workforce and employment matters affecting clinical and non-clinical staff
- Healthcare facilities development, licensing and operations
Market recognitions
24